Team Ovary, Memorial Sloan Kettering Cancer Center

On this #MeetTheTeamMonday, we would like to highlight Dr. Dennis S. Chi, founder of #TeamOvaryMSK, surgeon extraordinaire, and overall unwavering fighter for women with ovarian cancer.

🎉 Big congrats to Dr. McPherson and Dr. Sohrab Shah’s team on their new Nature paper! Their work on whole-genome doubling in HGSOC offers key insights into disease evolution and treatment. Proud to have them as Team Ovary collaborators! 📖 nature.com/articles/s4158…

Just published: the RAMP 201 study that led to the first-ever FDA-approved treatment for recurrent low-grade serous ovarian cancer with a KRAS mutation. Avutometinib + defactinib represents a major milestone for this rare and hard-to-treat disease. 📄 pubmed.ncbi.nlm.nih.gov/40644648/

And that’s a wrap on possibly my hardest month of fellowship thus far (hours-wise) but also one of my most rewarding! So long Orange Team, hello 4th year of fellowship! #atyourcervix @VanceBroach @TeamOvary_MSK @MSKCancerCenter

Humbled to get this and be a part of such an amazing group of doctors. Can’t make things better alone!! @TeamOvary_MSK @TeamEndo_MSK @MSKCancerCenter

Exciting data for the ovarian cancer community! The final results of the ARIEL3 Phase 3 trial evaluating #rucaparib as maintenance treatment in platinum-sensitive, recurrent ovarian carcinoma are now published. Read the full study: sciencedirect.com/science/articl… #ovarian #Cancer #ARIEL3

Promising combo of Pembro + Olaparib in p53 aberrant/CN-H #endometrialcancer presented by @MariaRubinstein at #ASCO25! We need more biomarkers to find those long term responders. @TeamEndo_MSK @TeamOvary_MSK @MSK_DeptOfMed

So proud of @saramoufarrij1 who is teaching us all about uterine LMS under the guidance of the one and only #marteehensley! @TeamEndo_MSK @TeamOvary_MSK @MSKCancerCenter @MSK_DeptOfMed

Get ready for the results our @PCORI funded trial comparing music therapy with cognitive behavioral therapy for anxiety symptoms in cancer survivors.

Read more about research from @AliciaLatham10 aimed to investigate the potential of Pap-derived #ctDNA (Pap-ctDNA) as a novel noninvasive tool for EC detection from @ASCO. #ASCO25

Check out @ariadnaroque8 and her awesome #ASCO25 poster building on work from @TeamOvary_MSK looking at #breastcancer after #ovariancancer in this with germline mutations in non-BRCA HR genes, shockingly none! @MSKCancerCenter @MSK_DeptOfMed

Fantastic work currently being presented @ASCO on a very important topic in #endometrialcancer by @WeillCornell resident Dr. Judy Wang. @YingLiu88 @TeamEndo_MSK

🚨Today kicks off #ASCO25. Follow along on our MSK social channels from May 30-June 3 for onsite updates, and read about the latest #cancerresearch from our MSK experts here: bit.ly/43lJ7qA (@ASCO)

Team Ovary’s @VanceBroach would make a fantastic addition to the IGCS Board of Directors. Voting closes June 10, so don’t miss your opportunity to cast your ballot. @TeamOvary_MSK @TeamEndo_MSK Read more about Dr. Broach and his vision here: igcs.org/board-of-direc…

Learning 👩‍🏫from three SCT past presidents and president elect @AlexiaIasonos at #MSKBiostats seminar series. Discussing 💬patient centric #ClinicalTrials @SCTorg

Important new study of prognostic implications of estrogen receptor (ER) expression in no specific molecular profile (NSMP) #endometrial cancer. ER+ was associated with better survival outcomes in the NSMP group. @AmirMomeniBr @TeamEndo_MSK pubmed.ncbi.nlm.nih.gov/40414144/

For those who were unable to attend the 2025 @ESGO_society meeting earlier this year, please take a look at these highlights with experts in key areas of gynecologic oncology, including @aburustummd discussing fertility preservation. @TeamEndo_MSK pubmed.ncbi.nlm.nih.gov/40409204/

Fantastic work for a very important clinical trial in patients with #ovarian cancer by @zivanovicmd and team in Heidelberg! @TeamOvary_MSK

In a new paper @Moe_ByrneMD and team assessed feasibility of identifying mutations (TM) in peritoneal washings in #endometrial cancer. Mutational analysis is feasible, and a substantial subset with suspicious washings had TMs detected. @TeamEndo_MSK pubmed.ncbi.nlm.nih.gov/40347837/

We were so fortunate to have a fantastic discussion with world-renowned expert Dr. Pei Hui MD PhD regarding diagnosis and management of gestational trophoblastic neoplasia as part of our departmental lecture series program. @TeamOvary_MSK @TeamEndo_MSK

Most uterine carcinosarcomas have detectable TROP2 expression. In an innovative study by @saramoufarrij1 and team, organoid models showed encouraging response to TROP2 targeted antibody drug conjugate sacituzumab govitecan. @TeamOvary_MSK @TeamEndo_MSK pubmed.ncbi.nlm.nih.gov/40344963/